Stryker (NYSE:SYK) Price Target Lowered to $400.00 at Citizens Jmp

by · The Cerbat Gem

Stryker (NYSE:SYK – Get Free Report) had its price objective lowered by investment analysts at Citizens Jmp from $440.00 to $400.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “market outperform” rating on the medical technology company’s stock. Citizens Jmp’s target price would indicate a potential upside of 19.06% from the stock’s current price.

A number of other brokerages also recently issued reports on SYK. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday. Citigroup restated an “outperform” rating on shares of Stryker in a report on Monday. Needham & Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada reduced their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $386.28.

Check Out Our Latest Stock Report on SYK

Stryker Price Performance

Shares of NYSE SYK traded up $10.27 during mid-day trading on Monday, reaching $335.97. The company’s stock had a trading volume of 308,293 shares, compared to its average volume of 2,364,750. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker has a 52 week low of $281.00 and a 52 week high of $396.86. The stock has a fifty day moving average of $317.28 and a two-hundred day moving average of $334.73. The firm has a market capitalization of $128.80 billion, a PE ratio of 34.66, a P/E/G ratio of 2.08 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the company posted $3.13 earnings per share. Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker will post 15.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Varma Mutual Pension Insurance Co lifted its position in shares of Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares in the last quarter. QRG Capital Management Inc. increased its holdings in Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after acquiring an additional 4,186 shares in the last quarter. Fulton Breakefield Broenniman LLC raised its position in Stryker by 41.3% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 50,123 shares of the medical technology company’s stock worth $17,617,000 after acquiring an additional 14,641 shares during the period. Swedbank AB lifted its holdings in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Further Reading